$72.67
0.04%
Nasdaq, Nov 20, 04:00 pm EST. Closed.

Bio-Techne Corporation Stock price

$72.67
+0.09 0.12% 1M
+25.97 55.61% 6M
+13.86 23.57% YTD
+13.94 23.74% 1Y
+9.08 14.28% 3Y
-49.74 40.63% 5Y
+46.52 177.84% 10Y
+58.71 420.37% 20Y
Nasdaq, Closing price Fri, Nov 20 2026
-0.03 0.04%

AI Insights on Bio-Techne Corporation Insights AI Insights on Bio-Techne Corporation

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Bio-Techne Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,086 stocks worldwide.

Key metrics

Basic
Market capitalization
$11.4b
Enterprise Value
$11.4b
Net debt
positive
Cash
$264.7m
Shares outstanding
156.1m
Valuation
P/E
62.6
P/S | estimate
9.4 | 8.8
EV/Sales | estimate
9.3 | 8.8
EV/FCF | ex SBC
43.1 | 51.2
P/B
5.4
Dividends
DPS
$0.32
Yield 1Y | 5Y
0.4% | 0.4%
Growth 1Y | 5Y
0.0% | 0.0%
Payout 1Y | 3Y
27.6% | 36.0%
Increased
0 Years
Financials
Revenue | estimate
$1.2b | $1.3b
EBITDA
$383.5m
EBIT
$286.2m
Net Income
$181.9m
Free Cash Flow | ex SBC
$263.2m | $221.9m
Growth
Revenue | estimate
-0.4% | 6.6%
EBITDA
2.3%
EBIT
8.0%
Net Income
151.7%
Free Cash Flow
2.6%
Margin
Gross
66.2%
EBITDA
31.6%
EBIT
23.6%
Net
15.0%
Free Cash Flow | ex SBC
21.7% | 18.3%
Financial Health
Equity Ratio
81.5%
Return on Equity
8.6%
ROCE
11.8%
ROIC
9.6%
Debt/Equity
0.1
Share-Based Compensation & Dilution
SBC | % of Revenue
$41.4m | 3.4%
SBC as % of FCF
15.7%
SBC Growth 1Y
1.3%
Share Count Growth 1Y
0.7%
Shareholder Yield
-0.3%
More
EPS
$1.2
FCF per Share
$1.7
Short interest
4.9%
Employees
3k
Rev per Employee
$390.0k

Bio-Techne Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Bio-Techne Corporation forecast:

15x Hold
79%
4x Sell
21%

Analyst Opinions

19 Analysts have issued a Bio-Techne Corporation forecast:

Hold
79%
Sell
21%

Bio-Techne Corporation Events

Past Events
JUN
25
Bio-Techne Corporation, Merck KGaA - M&A Call
5 months ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
6
Q3 2026 Earnings Call
7 months ago
MAR
10
Leerink Global Healthcare Conference 2026
9 months ago
MAR
3
TD Cowen 46th Annual Health Care Conference
9 months ago
FEB
4
Q2 2026 Earnings Call
10 months ago
JAN
13
44th Annual J.P. Morgan Healthcare Conference
10 months ago
DEC
9
53rd Annual Nasdaq Investor Conference
12 months ago
DEC
3
Citi Annual Global Healthcare Conference 2025
12 months ago
DEC
2
Evercore 8th Annual Healthcare Conference
12 months ago
NOV
20
Jefferies London Healthcare Conference 2025
about one year ago
NOV
18
Stephens Annual Investment Conference 2025
about one year ago
NOV
11
Stifel 2025 Healthcare Conference
about one year ago
NOV
10
UBS Global Healthcare Conference 2025
about one year ago
NOV
5
Q1 2026 Earnings Call
about one year ago

Financial data from Bio-Techne Corporation

Jun '26
+/-
%
1,215 1,215
0% 0%
100%
- Direct Costs 410 410
0% 0%
34%
805 805
1% 1%
66%
- Selling and Administrative Expenses 424 424
5% 5%
35%
- Research and Development Expense 95 95
5% 5%
8%
384 384
2% 2%
32%
- Depreciation and Amortization 97 97
11% 11%
8%
EBIT (Operating Income) EBIT 286 286
8% 8%
24%
Net Profit 182 182
152% 152%
15%

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Techne Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bio-Techne Corporation Stock News

Neutral
PRNewsWire
●
17 days ago
MINNEAPOLIS, Nov. 3, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2026. The quarterly dividend will be payable November 23, 2026, to all common shareholders of record at the close of business on November 13, 2026, provided Bio-Techne's previously announced tra...
Neutral
PRNewsWire
●
about one month ago
Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America Combined capabilities across Bristol, St. Paul and Minneapolis support customers from discovery through commercial manufacturing MINNEAPOLIS, Oct. 8, 2026 /PRNewswire/ -- ...
Neutral
PRNewsWire
●
about 2 months ago
MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the "Merger Agreement") at a Special Meeting of Shareholde...
More Bio-Techne Corporation News

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Head office United States
CEO Mr. Kelderman
Employees 3,100
Founded 1976
Website www.bio-techne.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today